Honestly I don´t think that this is going to be successful. If you have a look at the sample-letter you can see that it´s written very general- but every country, sometimes every city or district has its own special and local regulations regarding clinical trials (additionally to the general ones). Furthermore there are countries where clinical trials which have not been successful must be published as well, e.g. Austria.
Regarding amendments 193 and 253: I don´t think that it´s realistic, that detailed clicial trial reports are published and available for everyone, finally they also include senitive sponsor data which is protected from competitors.
The initative is interesting itself and there seems to be a strong need of greater transparency, as the non-publication of results is common and the availability of results in the most popular databse (ClinicalTrials.gov) is poor. http://www.bmj.com/content/347/bmj.f6104
Here is what AllTrials propose to do:
"• If you live in Europe take 10 minutes to write to your health minister, here's why: the EU Clinical Trials Regulation is going to be discussed next week. We need health ministers to ensure that the really good progress towards ensuring all clinical trials conducted in Europe are registered before they begin and results from them are made publicly available is not lost. More here.
• Donate to our fundraising appeal - we're more than half way to getting a video to spread the campaign worldwide made. Please help us produce that here.
• Make sure your organisation has joined the AllTrials campaign - if they haven't, ask them. There's a list here."
Indeed, it sounds to me not sufficient to influence the transparency.
French trial sponsors are urged to bolster clinical trial transparency
A working group urged that results should be published in a registry within a year after a study is completed...
"In the latest bid for clinical trial transparency, a French government working group has recommended a sweeping plan to publicize study data and issue guidelines for ensuring that results are made available on a widespread and timely basis.
Notably, the working group urged that clinical trial results should be published in a registry within a year after a study is completed. The French National Agency for the Safety of Medicines and Health Products was also encouraged to issue reminders to companies, universities, and others about posting results. And trial sponsors should be persuaded to incorporate posting obligations in clinical research training..."